Vacca Michele, D'Amore Simona, Graziano Giusi, D'Orazio Andria, Cariello Marica, Massafra Vittoria, Salvatore Lorena, Martelli Nicola, Murzilli Stefania, Lo Sasso Giuseppe, Mariani-Costantini Renato, Moschetta Antonio
Fondazione Mario Negri Sud, Santa Maria Imbaro (Chieti), Chieti, Italy; Unit of General Pathology, Aging Research Center (Ce.S.I.), "Gabriele D'Annunzio" University and Foundation, Chieti, Italy; Interdisciplinary Department of Medicine, "Aldo Moro" University of Bari, Bari, Italy.
National Cancer Institute, IRCCS Oncologico "Giovanni Paolo II", Bari, Italy.
PLoS One. 2014 Aug 12;9(8):e104449. doi: 10.1371/journal.pone.0104449. eCollection 2014.
BACKGROUND & AIMS: Liver regeneration (LR) is a valuable model for studying mechanisms modulating hepatocyte proliferation. Nuclear receptors (NRs) are key players in the control of cellular functions, being ideal modulators of hepatic proliferation and carcinogenesis.
METHODS & RESULTS: We used a previously validated RT-qPCR platform to profile modifications in the expression of all 49 members of the NR superfamily in mouse liver during LR. Twenty-nine NR transcripts were significantly modified in their expression during LR, including fatty acid (peroxisome proliferator-activated receptors, PPARs) and oxysterol (liver X receptors, Lxrs) sensors, circadian masters RevErbα and RevErbβ, glucocorticoid receptor (Gr) and constitutive androxane receptor (Car). In order to detect the NRs that better characterize proliferative status vs. proliferating liver, we used the novel Random Forest (RF) analysis to selected a trio of down-regulated NRs (thyroid receptor alpha, Trα; farsenoid X receptor beta, Fxrβ; Pparδ) as best discriminators of the proliferating status. To validate our approach, we further studied PPARδ role in modulating hepatic proliferation. We first confirmed the suppression of PPARδ both in LR and human hepatocellular carcinoma at protein level, and then demonstrated that PPARδ agonist GW501516 reduces the proliferative potential of hepatoma cells.
Our data suggest that NR transcriptome is modulated in proliferating liver and is a source of biomarkers and bona fide pharmacological targets for the management of liver disease affecting hepatocyte proliferation.
肝再生(LR)是研究调节肝细胞增殖机制的重要模型。核受体(NRs)是细胞功能调控的关键因子,是肝脏增殖和致癌作用的理想调节因子。
我们使用先前验证的RT-qPCR平台,分析了小鼠肝脏在肝再生过程中NR超家族所有49个成员的表达变化。29个NR转录本在肝再生过程中的表达有显著改变,包括脂肪酸(过氧化物酶体增殖物激活受体,PPARs)和氧化甾醇(肝脏X受体,Lxrs)感受器、昼夜节律主调控因子RevErbα和RevErbβ、糖皮质激素受体(Gr)和组成型雄烷受体(Car)。为了检测能更好地表征增殖状态与增殖肝脏的核受体,我们使用新型随机森林(RF)分析方法,选择了三个下调的核受体(甲状腺激素受体α,Trα;法尼醇X受体β,Fxrβ;PPARδ)作为增殖状态的最佳判别指标。为验证我们的方法,我们进一步研究了PPARδ在调节肝脏增殖中的作用。我们首先在蛋白质水平证实了肝再生和人类肝细胞癌中PPARδ均受到抑制,然后证明PPARδ激动剂GW501516降低了肝癌细胞的增殖潜能。
我们的数据表明,核受体转录组在增殖肝脏中受到调节,是影响肝细胞增殖的肝脏疾病管理的生物标志物和真正药理学靶点的来源。